<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES
EXCHANGE ACT OF 1934 (THE EXCHANGE ACT)
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
------------------------------------------------------
Delaware 13-4087132
(State of Incorporation or Organization) (I.R.S. Employer Identification No.)
---------------------------------------- ------------------------------------
5 Kiryat Mada, Har Hotzvim,
Jerusalem, Israel 91236
(Address of Principal Executive Offices) (Zip Code)
---------------------------------------- ------------------------------------
If this form relates to the If this form relates to the
registration of a class of registration of a class of
securities pursuant to Section securities pursuant to Section
12(b) of the Exchange Act 12(g) of the Exchange Act and is
and is effective pursuant to effective pursuant to General
General Instruction A.(c), Instruction A.(d), please check
please check the following box. [ ] the following box. [X]
----------
Securities Act registration statement file number to which this form relates:
333-37402
(If applicable)
Securities to be registered pursuant to Section 12(b) of the Exchange Act:
Title of Each Class Name of Each Exchange on Which
to be so Registered Each Class is to be Registered
------------------- ------------------------------
None Inapplicable
---------------------------------------- ------------------------------------
Securities to be registered pursuant to Section 12(g) of the Exchange Act:
Title of Each Class Name of Each Exchange on Which
to be so Registered Each Class is to be Registered
------------------- ------------------------------
Common Stock, $.001 par value per share Nasdaq National Market
1
<PAGE>
Item 1. Description of Registrant's Securities to be Registered
The description of the securities to be registered hereby as set forth
under the caption "Description of Capital Stock" in (i) the prospectus (subject
to completion) dated May 19, 2000, and included in Part I of the Registration
Statement (Registration No. 333-37402) on Form S-1 (as amended, the
"Registration Statement") of the registrant filed with the Securities and
Exchange Commission (the "Commission") pursuant to the Securities Act of 1933,
as amended (the "Securities Act"), and (ii) the related final form of the
prospectus to be filed with the Commission pursuant to Rule 424(b) of the
Securities Act, which is incorporated herein by reference.
Item 2. Exhibits
The following exhibits are filed as part of this registration
statement:
Exhibit No. Exhibit Description
----------- -------------------
3.1* Amended and Restated Certification of Incorporation
of the Company
3.2* By-Laws of the Company
* Previously filed with the Commission as an exhibit to the Registration
Statement and incorporated herein by reference pursuant to Rule 12b-32(a) of the
Exchange Act and Rule 102 of Regulation S-T.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities
Exchange Act of 1934, the registrant has caused this registration statement to
be signed on its behalf by the undersigned, thereto duly authorized.
KERYX BIOPHARMACEUTICALS, INC.
Date: June 28, 2000 By: /s/ Morris Laster
--------------------------------
Name: Morris Laster, M.D.
Title: Chief Executive Officer
3
